Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1539-0829
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease ; volume:22 ; number:1 ; day:3 ; month:2 ; year:2022 ; pages:39-52 ; date:1.2022
Current diabetes reports ; 22, Heft 1 (3.2.2022), 39-52, 1.2022
- Urheber
-
Bailey, Clifford J.
Day, Caroline
Bellary, Srikanth
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s11892-021-01442-z
- URN
-
urn:nbn:de:101:1-2022052907213936230325
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:27 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Bailey, Clifford J.
- Day, Caroline
- Bellary, Srikanth
- SpringerLink (Online service)
Ähnliche Objekte (12)
Renal protection: a leading mechanism for cardiovascular benefit in patients treated with SGLT2 inhibitors
SGLT2 inhibitors improve kidney function and morphology by regulating renal metabolic reprogramming in mice with diabetic kidney disease
Early Initiation of SGLT2 Inhibitors in Acute Heart Failure: a Focus on Diuresis and Renal Protection
Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury
Angiotensin Receptor-Neprilysin Inhibitor for Chronic Kidney Disease: Strategies for Renal Protection
Can SGLT2 inhibitors answer unmet therapeutic needs in chronic kidney disease?
SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 Diabetes
SGLT2 Inhibitors – The New Standard of Care for Cardiovascular, Renal and Metabolic Protection in Type 2 Diabetes: A Narrative Review
Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape
Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study
SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease
Direct cardiac effects of SGLT2 inhibitors
Renal protection: a leading mechanism for cardiovascular benefit in patients treated with SGLT2 inhibitors
SGLT2 inhibitors improve kidney function and morphology by regulating renal metabolic reprogramming in mice with diabetic kidney disease
Early Initiation of SGLT2 Inhibitors in Acute Heart Failure: a Focus on Diuresis and Renal Protection
Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury
Angiotensin Receptor-Neprilysin Inhibitor for Chronic Kidney Disease: Strategies for Renal Protection
Can SGLT2 inhibitors answer unmet therapeutic needs in chronic kidney disease?
SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 Diabetes
SGLT2 Inhibitors – The New Standard of Care for Cardiovascular, Renal and Metabolic Protection in Type 2 Diabetes: A Narrative Review
Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape
Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study
SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease
Direct cardiac effects of SGLT2 inhibitors
Renal protection: a leading mechanism for cardiovascular benefit in patients treated with SGLT2 inhibitors
SGLT2 inhibitors improve kidney function and morphology by regulating renal metabolic reprogramming in mice with diabetic kidney disease
Early Initiation of SGLT2 Inhibitors in Acute Heart Failure: a Focus on Diuresis and Renal Protection
Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury
Angiotensin Receptor-Neprilysin Inhibitor for Chronic Kidney Disease: Strategies for Renal Protection
Can SGLT2 inhibitors answer unmet therapeutic needs in chronic kidney disease?
SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 Diabetes
SGLT2 Inhibitors – The New Standard of Care for Cardiovascular, Renal and Metabolic Protection in Type 2 Diabetes: A Narrative Review
Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape
Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study
SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease